HNRNPC and ovarian cancer: Importantly, the ROC curve showed that increased expression of HNRNPC could perfectly predict response to paclitaxel for ovarian cancer patients based on relapse‐free survival (RFS) at 6 months (AUC =0.839, p = 5.0e‐6, Figure 2k and Table 1), RFS at 12 months (AUC =0.802, p = 2.4e‐4, see also Table S2) and pathological response (AUC =0.803, p = 2.4e‐4, Figure 2l), while decreased expression of YTHDC1 could predict response to paclitaxel on RFS at 6 months (AUC =0.707, p = 1.5e‐3, Table 1).